{"id":907878,"date":"2025-11-10T19:29:07","date_gmt":"2025-11-11T00:29:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/mallinckrodt-reports-third-quarter-2025-financial-results\/"},"modified":"2025-11-10T19:29:07","modified_gmt":"2025-11-11T00:29:07","slug":"mallinckrodt-reports-third-quarter-2025-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mallinckrodt-reports-third-quarter-2025-financial-results\/","title":{"rendered":"Mallinckrodt Reports Third Quarter 2025 Financial Results"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Delivers Third Quarter Net Sales of $753.1 Million<\/span>, Driven by Acthar\u00ae<\/sup> Gel (repository corticotropin injection) Growth and the Inclusion of Two Months of Endo Product Net Sales<\/i>\n <\/p>\n

\n Expects Fourth Quarter 2025 Net Sales of $485 Million<\/span> to $505 Million<\/span> and Adjusted EBITDA\u00a0of $155 Million<\/span> to $165 Million<\/span> for Keenova<\/i>\n <\/p>\n

\n Raises Full-Year Acthar Gel Net Sales Growth Guidance to 30% to 35%, Reflecting Strong Brand Momentum<\/i>\n <\/p>\n

\n Conference Call and Webcast Today at 8:00 a.m. ET<\/span><\/i>\n <\/p>\n

\n
\n DUBLIN<\/span>
\n <\/span>, Nov. 10, 2025<\/span><\/span> \/PRNewswire\/ — Mallinckrodt<\/span> plc (“Mallinckrodt<\/span>” or the “Company”) today reported its financial results for the third quarter of 2025, which include combined business results following the completion of Mallinckrodt’s<\/span> merger with Endo, Inc. (“Endo”) on July 31, 2025<\/span>. As announced today in a separate press release, Mallinckrodt<\/span> has completed the spin-off of its combined generics and sterile injectables businesses under the name Par Health, Inc. (“Par Health”) and is introducing the combined branded therapeutics business, Keenova Therapeutics (“Keenova”).<\/p>\n

\n

\n
\n \"Mallinckrodt
\n <\/a>\n <\/p>\n<\/p><\/div>\n

“We are excited to begin our next chapter as Keenova Therapeutics, a pure-play branded therapeutics company focused on addressing unmet patient needs,” said Siggi Olafsson<\/span>, President and Chief Executive Officer. “The third-quarter results of our branded therapeutics portfolio reflect the promise that our future holds. Our team delivered another quarter of robust double-digit growth in Acthar Gel, driven by growing demand and a broadening prescriber base. We were also pleased to advance our XIAFLEX\u00ae<\/sup> (collagenase clostridium histolyticum) pipeline with the initiation of a new clinical program focused on hammertoe for which we have already recruited over 30 patients. We are on track to have a strong finish to the year, as reflected in the fourth quarter guidance we are providing for Keenova.”<\/p>\n

Mr. Olafsson added, “Following the merger with Endo and the Par Health spin-off, we are moving forward with enhanced resources, focus and scale to bring important therapies to our patients. The energy our teams have for Keenova’s future is inspiring, and I am grateful for their deep dedication as we strive to deliver greater benefits for our patients and enhanced value for partners and shareholders.”<\/p>\n

\n Segment Updates<\/b>\n <\/p>\n

The Company’s consolidated and segment operating results for the three months ended September\u00a026, 2025 reflect the inclusion of two months of Endo’s performance. The Company operated its business in three reportable segments, as a result of the merger:<\/p>\n